Nationwide Trial of Diovan for Patients Suffering Heart Failure To Be Launched in 2005

Published: 2004-12-06 07:00:00

Updated: 2004-12-06 07:00:00

Norvatis Korea announced it will launch a nationwide clinical studies of Diovan, an angiotensin receptor blocker (ARB) based anti-hypertension drug, for the treatment of patients suffering heart failure (HF).

The nationwide studies will be based on Valsartan Heart Failure Trial (Val-HeFT), dee...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK